Automated heparin-delivery system to control activated partial thromboplastin time: Evaluation in normal volunteers

Circulation

Volumn 99, Issue 6, 1999, Pages 751-756

  Cannon, Christopher P ^a,e   Dingemanse, Jasper ^b   Kleinbloesem, Cornelis H ^b   Jannett, Thomas ^c   Curry, Kenneth M ^d   Valcke, Christian P ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Clin Pharma Research AG   (Switzerland)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Gensia Inc   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anticoagulants; Coagulation; Heparin

Indexed keywords

HEPARIN;

ADULT; ALGORITHM; ANTICOAGULATION; ARTICLE; AUTOMATION; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TITRIMETRY; VOLUNTEER;

EID: 0032911532     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.6.751     Document Type: Article

References (13)

1. Hirsh J, Fuster V. Guide to anticoagulation therapy, 1: heparin. Circulation. 1994;89:1449-1468.
2. Granger CB, Hirsh J, Califf RM, Col J, White HD, Betriu A, Woodlief LH, Lee KL, Bovill EG, Simes J, Topol EJ, for the GUSTO-I Investigators. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation. 1996;93:870-878.
3. Cannon CP, Antman EA. Heparin and low molecular weight heparin in acute coronary syndromes and angioplasty. In: Crawford MH, ed. Cardialogy Clinics: Annual of Drug Therapy. Philadelphia, Pa: WB Saunders Co; 1997;105-119.
4. Becker RC, Cyr J, Corrao JM, Ball SP. Bedside coagulation monitoring in heparin-treated patients with active thromboembolic disease: a coronary care unit experience. Am Heart J. 1994;128:719-723.
5. Flaker GC, Bartolozzi J, Davis V, McCabe CH, Cannon CP. Use of a standardized nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. Arch Intern Med. 1994; 154:1492-1496.
6. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med. 1993;119:874-881.
7. Mungall DR, Anbe D, Forrester PL, Luoma T, Genovese R, Mahan J, Le Blanc S, Penney JB. A prospective randomized comparison of the accuracy of computer-assisted versus GUSTO nomogram-directed heparin therapy. Clin Pharmacol Ther. 1994;55:591-596.
8. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 1996;94:911-921.
9. Becker RC, Borzak S, Held C, Ball SP, Voyce SJ, Jesse RL, Hendel RC, Lee V, Spencer FA, Ma Y, Hurley TG, Hebert JR. A randomized trial of weight-adjusted heparin dosing and bedside coagulation monitoring in patient with thrombotic disorders. Circulation 1997:96(suppl I):I-386. Abstract.
10. St. Peter JV, Plachetka J, Halstenson CE, Swan SK, Walenga JM. Heparin: aPTT/ACT PK/PD in normal human subjects. Presented at the American Society of Clinical Pharmacological Therapy, 96th Annual Meeting; March 1995; San Diego, Calif.
11. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison of non-Bayesian methods. J Pharmacol Sci. 1982;71:1344-1348.
12. Jannett TC, Sanders PW, Shanklin N, Wise MG. Adaptive control of anticoagulation during hemodialysis. Kidney Int. 1994;45:912-915.
13. Mungall D, Floyd R. Bayesian forecasting of APTT response to continuously infused heparin with and without warfarin administration. J Clin Pharmacol. 1989;29:1043-1047.